11-12 September 2018 //  Lancaster Royal Hotel, London


Alexander Huber

Dr Alexander Huber

Global CMC Head & Director, Cell & Gene Therapy Unit, Novartis Pharma AG

Dr. Alexander Huber started his career in the pharmaceutical industry at the research department of F. Hoffmann- La Roche Ltd in Basel, Switzerland in 2002. He held several positions with increasing responsibility and became plant manager for lyophilized products in 2007. 2009 he joined Novartis Pharma technical research and development (TRD) as director of the global centre of excellence for parenteral clinical supply. In 2013 he changed to the newly founded “Cell & Gene-Therapy Unit” as global CMC head. There he is mainly responsible for the management of CMOs to ensure supply of critical materials for Novartis portfolio of cell- and gene therapy projects such as viral vector, plasmids, serum and antibody coated beads.

Alexander received his PhD from the Federal Institute of Technology (ETH) Zürich in the field of molecular neuropharmacology, developing a first ex-vivo gene therapy approach against focal epilepsy in an animal model. He also holds a MBA from the same university.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad